Literature DB >> 12181624

Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis.

H Tsugeno1, H Tsugeno1, T Fujita, B Goto, T Sugishita, Y Hosaki, K Ashida, F Mitsunobu, Y Tanizaki, Y Shiratori.   

Abstract

Despite an intriguing understanding of trabecular bone dynamics, little is known about corticosteroid-induced cortical bone loss and fractures. Recently, we verified a steroid-induced decrease in cortical bone volume and density using peripheral quantitative computed tomography (pQCT) in adult asthmatic patients given oral corticosteroids. Subsequently, the pQCT parameters and presence of vertebral fractures were investigated to further clarify the role of cortical bone quality in fractures in 86 postmenopausal (>5 years after menopause) asthmatic patients on high-dose oral steroid (>10 g cumulative oral prednisolone) (steroid group) and 194 age-matched controls (control group). Cortical and trabecular bone was subjected to measurement of various parameters using pQCT (Stratec XCT960). Relative Cortical Volume (RCV) was calculated by dividing the cortical area by the total bone area. Strength Strain Index (SSI) was determined in the radius based on the density distribution around the axis. Spinal fracture was assessed on lateral radiographs. Patients treated with high doses of oral steroid (>10 g cumulative oral prednisolone) were found to have an increased risk of fracture compared with control women receiving no steroid medication (odds ratio, 8.85; 95% CI, 4.21-18.60) after adjustment was made for years since menopause, body mass index and RCV. In both groups, the diagnostic and predictive ability of the pQCT parameters for vertebral fracture was assessed by the areas under their receiver operating characteristic (ROC) curves. All parameters were found to be significant predictors ( p<0.0001) in the control group. In the steroid group, however, the cortical bone mineral density (BMD) ( p = 0.001), RCV ( p<0.0001) and SSI ( p = 0.001) were found to be significant predictors, but not trabecular BMD ( p = 0.176). For comparison between the two groups, thresholds of all parameters for vertebral fracture were also calculated by the point of coincidence of sensitivity with specificity in ROC testing and the 90th percentile value. Although a rise in fracture threshold in the steroid group was suggested, considerable difference in the values obtained by the two methods of calculation precluded any conclusion. High-dose oral steroid administration was associated with an increased risk of fracture. Cortical bone parameters obtained by pQCT could play a role as good predictors of future corticosteroid-induced vertebral fractures.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181624     DOI: 10.1007/s001980200088

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  10 in total

1.  Osteopenia in the maxillofacial area: a study in sheep.

Authors:  E Veigel; R J Moore; M R Zarrinkalam; D Schulze; S Sauerbier; R Schmelzeisen; P J Voss
Journal:  Osteoporos Int       Date:  2010-05-26       Impact factor: 4.507

2.  Risedronate improves bone architecture and strength faster than alendronate in ovariectomized rats on a low-calcium diet.

Authors:  Tetsuo Yano; Mei Yamada; Tomoyuki Konda; Makoto Shiozaki; Daisuke Inoue
Journal:  J Bone Miner Metab       Date:  2013-12-20       Impact factor: 2.626

Review 3.  A Comparison of Peripheral Imaging Technologies for Bone and Muscle Quantification: a Mixed Methods Clinical Review.

Authors:  Andy Kin On Wong
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

4.  Symptomatic refractures after vertebroplasty in patients with steroid-induced osteoporosis.

Authors:  M I Syed; N A Patel; S Jan; A Shaikh; B Grunden; K Morar
Journal:  AJNR Am J Neuroradiol       Date:  2006-10       Impact factor: 3.825

5.  Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naive postmenopausal women.

Authors:  Kuo-Chiang Lian; Thomas F Lang; Joyce H Keyak; Gunnard W Modin; Qaisar Rehman; Loi Do; Nancy E Lane
Journal:  Osteoporos Int       Date:  2004-09-28       Impact factor: 4.507

6.  Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case-control study using HR-pQCT.

Authors:  X L Tang; L Qin; A W Kwok; T Y Zhu; E W Kun; V W Hung; J F Griffith; P C Leung; E K Li; L-S Tam
Journal:  Osteoporos Int       Date:  2012-10-27       Impact factor: 4.507

7.  Validation of the sheep as a large animal model for the study of vertebral osteoporosis.

Authors:  M R Zarrinkalam; H Beard; C G Schultz; R J Moore
Journal:  Eur Spine J       Date:  2008-11-18       Impact factor: 3.134

8.  Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate.

Authors:  A Bitto; B P Burnett; F Polito; R M Levy; H Marini; V Di Stefano; N Irrera; M A Armbruster; L Minutoli; D Altavilla; F Squadrito
Journal:  Br J Pharmacol       Date:  2009-03-19       Impact factor: 8.739

9.  Long-term fracture risk following adult-onset asthma: a population-based study.

Authors:  L Joseph Melton; Ashok Patel; Sara J Achenbach; Ann L Oberg; John W Yunginger
Journal:  Osteoporos Int       Date:  2004-02-24       Impact factor: 4.507

Review 10.  Cortical remodeling during menopause, rheumatoid arthritis, glucocorticoid and bisphosphonate therapy.

Authors:  Daniel Aeberli; Georg Schett
Journal:  Arthritis Res Ther       Date:  2013-03-21       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.